NO20031482D0 - Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer - Google Patents

Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer

Info

Publication number
NO20031482D0
NO20031482D0 NO20031482A NO20031482A NO20031482D0 NO 20031482 D0 NO20031482 D0 NO 20031482D0 NO 20031482 A NO20031482 A NO 20031482A NO 20031482 A NO20031482 A NO 20031482A NO 20031482 D0 NO20031482 D0 NO 20031482D0
Authority
NO
Norway
Prior art keywords
oxadiazoles
phosphodiesterase
inhibitors
thiadiazoles
new
Prior art date
Application number
NO20031482A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031482L (no
Inventor
Fabrice Vergne
Pierre Ducrot
Charles Andrianjara
Patrick Bernardelli
Edwige Lorthiois
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20031482D0 publication Critical patent/NO20031482D0/no
Publication of NO20031482L publication Critical patent/NO20031482L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20031482A 2000-10-02 2003-04-01 Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer NO20031482L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (fr) 2000-10-02 2000-10-02 Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7
PCT/EP2001/011330 WO2002028847A1 (fr) 2000-10-02 2001-10-01 Nouveaux thiadiazoles et oxadiazoles et utilisation de ceux-ci comme inhibiteurs de la phosphodiesterase de type 7

Publications (2)

Publication Number Publication Date
NO20031482D0 true NO20031482D0 (no) 2003-04-01
NO20031482L NO20031482L (no) 2003-04-01

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031482A NO20031482L (no) 2000-10-02 2003-04-01 Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer

Country Status (43)

Country Link
US (1) US7122565B2 (fr)
EP (2) EP1193261A1 (fr)
JP (1) JP4177098B2 (fr)
KR (1) KR100614158B1 (fr)
CN (1) CN1639141A (fr)
AP (1) AP1541A (fr)
AR (1) AR035347A1 (fr)
AT (1) ATE304003T1 (fr)
AU (2) AU2001289945B2 (fr)
BG (1) BG107654A (fr)
BR (1) BR0114391A (fr)
CA (1) CA2424279A1 (fr)
CZ (1) CZ2003857A3 (fr)
DE (1) DE60113283T2 (fr)
DK (1) DK1326853T3 (fr)
DZ (1) DZ3440A1 (fr)
EA (1) EA007179B1 (fr)
EC (1) ECSP034534A (fr)
EE (1) EE200300134A (fr)
ES (1) ES2247166T3 (fr)
GE (1) GEP20053459B (fr)
GT (1) GT200100196A (fr)
HN (1) HN2001000217A (fr)
HR (1) HRP20030247A2 (fr)
HU (1) HUP0301248A3 (fr)
IL (1) IL155122A0 (fr)
IS (1) IS6759A (fr)
MA (1) MA25916A1 (fr)
MX (1) MXPA03002839A (fr)
NO (1) NO20031482L (fr)
NZ (1) NZ524852A (fr)
OA (1) OA12518A (fr)
PA (1) PA8529501A1 (fr)
PE (1) PE20020419A1 (fr)
PL (1) PL366332A1 (fr)
PT (1) PT1326853E (fr)
SI (1) SI1326853T1 (fr)
SK (1) SK3812003A3 (fr)
SV (1) SV2003000633A (fr)
TN (1) TNSN01139A1 (fr)
WO (1) WO2002028847A1 (fr)
YU (1) YU24503A (fr)
ZA (1) ZA200302346B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044235A1 (fr) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Procedes de diagnostic de maladies associees a la phosphodiesterase 7a1 (pde7a1) humaine et moyens therapeutiques correspondants
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
AU2005258410B2 (en) 2004-07-01 2011-12-22 Daiichi Sankyo Company Limited Thienopyrazole derivative having PDE7 inhibitory activity
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
WO2007025177A2 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese par modulation de l'angiotensine
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0809244A2 (pt) * 2007-03-27 2014-09-23 Omeros Corp Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR102054899B1 (ko) 2010-11-08 2019-12-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
SG10201911989SA (en) * 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038089A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation d'un agent thérapeutique ayant une activité inhibitrice de phosphodiestérase-7 pour le traitement et la prévention de maladies associées à la fatigue, à l'épuisement et/ou à l'intolérance à l'effort chroniques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (fr)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
US6326378B1 (en) * 1998-02-17 2001-12-04 Roche Diagnostics Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives

Also Published As

Publication number Publication date
OA12518A (en) 2006-05-29
JP4177098B2 (ja) 2008-11-05
HUP0301248A2 (hu) 2003-10-28
NZ524852A (en) 2004-09-24
EA007179B1 (ru) 2006-08-25
AU8994501A (en) 2002-04-15
SI1326853T1 (sl) 2005-12-31
ATE304003T1 (de) 2005-09-15
DE60113283T2 (de) 2006-06-08
GT200100196A (es) 2002-07-18
MXPA03002839A (es) 2004-09-10
CA2424279A1 (fr) 2002-04-11
AP2003002764A0 (en) 2003-03-31
KR20030068542A (ko) 2003-08-21
YU24503A (sh) 2006-03-03
KR100614158B1 (ko) 2006-08-21
WO2002028847A1 (fr) 2002-04-11
EA200300333A1 (ru) 2003-10-30
DK1326853T3 (da) 2005-12-12
DZ3440A1 (fr) 2002-04-11
BG107654A (bg) 2003-12-31
HUP0301248A3 (en) 2005-06-28
ECSP034534A (es) 2003-07-25
AR035347A1 (es) 2004-05-12
IL155122A0 (en) 2003-10-31
MA25916A1 (fr) 2003-10-01
HRP20030247A2 (en) 2005-04-30
EE200300134A (et) 2003-08-15
NO20031482L (no) 2003-04-01
EP1326853A1 (fr) 2003-07-16
US7122565B2 (en) 2006-10-17
US20030045557A1 (en) 2003-03-06
GEP20053459B (en) 2005-02-25
EP1326853B1 (fr) 2005-09-07
BR0114391A (pt) 2003-06-24
DE60113283D1 (de) 2005-10-13
PA8529501A1 (es) 2003-06-30
TNSN01139A1 (en) 2005-11-10
SV2003000633A (es) 2003-04-03
ZA200302346B (en) 2004-08-04
PL366332A1 (en) 2005-01-24
CN1639141A (zh) 2005-07-13
EP1193261A1 (fr) 2002-04-03
ES2247166T3 (es) 2006-03-01
HN2001000217A (es) 2002-06-13
IS6759A (is) 2003-03-27
PT1326853E (pt) 2005-11-30
PE20020419A1 (es) 2002-07-18
JP2004510769A (ja) 2004-04-08
CZ2003857A3 (cs) 2004-02-18
SK3812003A3 (en) 2004-05-04
AU2001289945B2 (en) 2005-12-22
AP1541A (en) 2006-01-11

Similar Documents

Publication Publication Date Title
NO20031482D0 (no) Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer
NO20034187L (no) Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
NO20032465L (no) Nye mandelsyre-derivater og anvendelse derav som trombininhibitorer
NO20013452L (no) Benzoheterocykler og deres anvendelse som MEK-inhibitorer
NO20015113D0 (no) Nye forbindelser, deres fremstilling og anvendelse
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20022289L (no) Ny anvendelse og nye N-azabisykloamidderivater
NO20032830L (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celleproliferasjonsinhibitorer
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20014135L (no) Nye sulfonamidforbindelser og deres anvendelse
NO20052124D0 (no) Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
NO20013853D0 (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
NO20025504D0 (no) Nye tiokromanderivater og anvendelse derav som trombininhibitorer
NO20030243D0 (no) Nye forbindelser og deres anvendelse som glysintransportinhibitorer
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20023951D0 (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
NO20030813L (no) Bifenylderivater og deres anvendelse som integrininhibitorer
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
NO20025884D0 (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
NO20030812L (no) Bifenylderivater og anvendelse derav som integrininhibitorer
NO20025885D0 (no) 4,5-dihydro-tiazol-2-ylaminderivater og deres anvendelse som NO-syntaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application